COUNCIL DIRECTIVE 92/73/EEC
of 22 September 1992

widening the scope of Directives 65/65/EEC and 75/319/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products and laying down additional provisions on homeopathic medicinal products

THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100a thereof,

Having regard to the proposal from the Commission (1),

In cooperation with the European Parliament (2),

Having regard to the opinion of the Economic and Social Committee (3),

Whereas differences currently existing between the provisions laid down by law, regulation or administrative action in the Member States may hinder trade in homeopathic medicinal products within the Community and lead to discrimination and distortion of competition between manufacturers of these products;

Whereas the essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health;

Whereas, despite considerable differences in the status of alternative medicines in the Member States, patients should be allowed access to the medicinal products of their choice, provided all precautions are taken to ensure the quality and safety of the said products;

Whereas the anthroposophic medicinal products described in an official pharmacopoeia and prepared by a homoeopathic method are to be treated, as regards registration and marketing authorization, in the same way as homeopathic medicinal products;

Whereas the provisions of Directive 65/65/EEC (4) and the Second Directive 75/319/EEC (5), are not always appropriate for homeopathic medicinal products;

Whereas homeopathic medicine is officially recognized in certain Member States but is only tolerated in other Member States;

Whereas, even if homeopathic medicinal products are not always officially recognized, they are nevertheless prescribed and used in all Member States;

Whereas it is desirable in the first instance to provide users of these medicinal products with a very clear indication of their homeopathic character and with sufficient guarantees of their quality and safety;

Whereas the rules relating to the manufacture, control and inspection of homeopathic medicinal products must be harmonized to permit the circulation throughout the Community of medicinal products which are safe and of good quality;

Whereas, having regard to the particular characteristics of these medicinal products, such as the very low level of active principles they contain and the difficulty of applying to them the conventional statistical methods relating to clinical trials, it is desirable to provide a special, simplified registration procedure for those traditional homeopathic medicinal products which are placed on the market without therapeutic indications in a pharmaceutical form and dosage which do not present a risk for the patient;

Whereas, however, the usual rules governing the authorization to market medicinal products should be applied to homeopathic medicinal products placed on the market with therapeutic indications or in a form which may present risks which must be balanced against the desired therapeutic effect; whereas, in particular, those Member States which have a homeopathic tradition should be able to apply particular rules for the evaluation of the results of tests and trials intended to establish the safety and efficacy of these medicinal products provided that they notify them to the Commission,

HAS ADOPTED THIS DIRECTIVE:

CHAPTER I

Scope

Article 1

1. For the purposes of this Directive, 'homeopathic medicinal product' shall mean any medicinal product
CHAPTER II

Manufacture, control and inspection

Article 3

The provisions of Chapter IV of Directive 75/319/EEC shall apply to the manufacture, control, import and export of homeopathic medicinal products.

Article 4

The supervision measures and the sanctions provided for in Chapter V of Directive 75/319/EEC shall apply to homeopathic medicinal products, together with Articles 31 and 32 of the same Directive.

However, the proof of therapeutic efficacy referred to in Article 28 (1) (b) of the same Directive shall not be required for homeopathic medicinal products registered in accordance with Article 7 of this Directive or, where appropriate, admitted in accordance with Article 6 (2).

Article 5

Member States shall communicate to each other all the information necessary to guarantee the quality and safety of homeopathic medicinal products manufactured and marketed within the Community, and in particular the information referred to in Articles 30 and 33 of Directive 75/319/EEC.
2. In addition to the clear mention of the words 'homeopathic medicinal product', the labelling and, where appropriate, package insert for the medicinal products referred to in paragraph 1 shall bear the following, and no other, information:

— the scientific name of the stock or stocks followed by the degree of dilution, making use of the symbols of the pharmacopoeia used in accordance with Article 1 (1),

— name and address of the person responsible for placing the product on the market and, where appropriate, of the manufacturer,

— method of administration and, if necessary, route,

— expiry date, in clear terms (month, year),

— pharmaceutical form,

— contents of the sales presentation,

— special storage precautions, if any,

— a special warning if necessary for the medicinal product,

— manufacturer's batch number,

— registration number,

— 'homeopathic medicinal product without approved therapeutic indications',

— a warning advising the user to consult a doctor if the symptoms persist during the use of the medicinal product.

3. Notwithstanding paragraph 2, Member States may require the use of certain types of labelling in order to show:

— the price of the medicinal product,

— the conditions for refunds by social security bodies.

4. The criteria and rules of procedure provided for in Articles 5 to 12 of Directive 65/65/EEC shall apply by analogy to the special, simplified registration procedure for homeopathic medicinal products, with the exception of the proof of therapeutic efficacy.

Article 8

An application for special, simplified registration submitted by the person responsible for placing the product on the market may cover a series of medicinal products derived from the same homeopathic stock or stocks. The following documents shall be included with the application in order to demonstrate, in particular, the pharmaceutical quality and the batch-to-batch homogeneity of the products concerned:

— scientific name or other name given in a pharmacopoeia of the homeopathic stock or stocks, together with a statement of the various routes of administration, pharmaceutical forms and degree of dilution to be registered,

— dossier describing how the homeopathic stock or stocks is/are obtained and controlled, and justifying its/their homeopathic nature, on the basis of an adequate bibliography,

— manufacturing and control file for each pharmanceutical form and a description of the method of dilution and potentization,

— manufacturing authorization for the medicinal product concerned,

— copies of any registrations or authorizations obtained for the same medicinal product in other Member States;

— one or more specimens or mock-ups of the sales presentation of the medicinal products to be registered,

— data concerning the stability of the medicinal product.

Article 9

1. Homeopathic medicinal products other than those referred to in Article 7 of this Directive shall be authorized and labelled in accordance with Articles 4 to 21 of Directive 65/65/EEC including the provisions concerning proof of therapeutic effect and Articles 1 to 7 of Directive 75/319/EEC.

2. A Member State may introduce or retain in its territory specific rules for the pharmacological and toxicological tests and clinical trials of homeopathic medicinal products other than those referred to in Article 7 (1) in accordance with the principles and characteristics of homeopathy as practised in that Member State.

In this case, the Member State concerned shall notify the Commission of the specific rules in force.

CHAPTER IV

Final provisions

Article 10

1. Member States shall take the measures necessary to comply with this Directive by 31 December 1993. They shall forthwith inform the Commission thereof.

When Member States adopt the said measures, they shall contain a reference to this Directive or be accompanied by such reference when they are officially published. The
procedure for making such reference shall be adopted by the Member States.

2. Applications for registration or for marketing authorization for medicinal products covered by this Directive lodged after the date set in paragraph 1 shall comply with the provisions of this Directive.

3. Not later than 31 December 1995, the Commission shall present a report to the European Parliament and the Council concerning the application of this Directive.

Article 11
This Directive is addressed to the Member States.


For the Council
The President

R. NEEDHAM